Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27068
Full metadata record
???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
---|---|---|
dc.contributor.advisor | 賴美淑(Mei-Shu Lai),陳秀熙(Tony Hsiu-Hsi Chen) | |
dc.contributor.author | Chun-Ru Chien | en |
dc.contributor.author | 簡君儒 | zh_TW |
dc.date.accessioned | 2021-06-12T17:54:49Z | - |
dc.date.available | 2009-02-20 | |
dc.date.copyright | 2008-02-20 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-02-03 | |
dc.identifier.citation | Abe, Y., K. Hanai, et al. (2005). 'A computer-aided diagnosis (CAD) system in lung cancer screening with computed tomography.' Anticancer Res 25: 483-8.
Alberg, A. J., M. V. Brock, et al. (2005). 'Epidemiology of Lung Cancer: Looking to the Future.' J Clin Oncol 23: 3175-3185. Albert, J. (1996). 'Bayesian selection of log-linear models.' Canadian Journal of Statistics 24: 327-347. Auperin A, A. R., Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J (1999). 'Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.' N Engl J Med. 1999 Aug 12;341(7):476-84. Bach, P. B., J. R. Jett, et al. (2007). 'Computed tomography screening and lung cancer outcomes.' Jama 297: 953-61. Bach, P. B., G. A. Silvestri, et al. (2007). 'Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).' Chest 132: 69S-77S. Berry, D. A., K. A. Cronin, et al. (2005). 'Effect of screening and adjuvant therapy on mortality from breast cancer.' N Engl J Med 353: 1784-92. Black C, A. Bagust, et al. (2006). 'The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews.' Health Technol Assess 10: iii-iv, ix-x, 1-90. Black, W. C. (2007). 'Computed tomography screening for lung cancer: review of screening principles and update on current status.' Cancer 110: 2370-84. Black, W. C. and J. A. Baron (2007). 'CT screening for lung cancer: spiraling into confusion?' Jama 297: 995-7. Brawley, O. W. and B. S. Kramer (2005). 'Cancer Screening in Theory and in Practice.' J Clin Oncol 23: 293-300. Bray, I. (2002). 'Application of Markov chain Monte Carlo methods to projecting cancer incidence an mortality.' J R Stat Soc Ser C Appl Stat 51: 151-164. Cartman, M. L., A. C. Hatfield, et al. (2002). 'Lung cancer: district active treatment rates affect survival.' J Epidemiol Community Health 56: 424-9. Chang HY, C. C., Wang JD. (1999). 'Risk assessment of lung cancer and mesothelioma in people living near asbestos-related factories in Taiwan.' Arch Environ Health. 1999 May-Jun;54(3):194-201. Chen CJ, W. H., Chuang YC, Chang AS, Luh KT, Chao HH, Chen KY, Chen SG, Lai GM, Huang HH, Lee HH. (1990). 'Epidemiologic characteristics and multiple risk factors of lung cancer in Taiwan.' Anticancer Res. 1990 Jul-Aug;10(4):971-6. Chen CL, H. L., Chiou HY, Hsueh YM, Chen SY, Wu MM, Chen CJ; Blackfoot Disease Study Group. (2004). 'Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan.' JAMA. 2004;292(24):2984-90. Chen, H. Y., S. L. Yu, et al. (2007). 'A five-gene signature and clinical outcome in non-small-cell lung cancer.' N Engl J Med 356: 11-20. Chen TH, K. H., Yen MF, Lai MS, Tabar L, Duffy SW. (2000). 'Estimation of sojourn time in chronic disease screening without data on interval cases.' Biometrics. 2000 Mar;56(1):167-72. Cheng, T. Y., C. P. Wen, et al. (2002). 'The current status of smoking behavior in Taiwan: Data analysis from National Health Interview Survey in 2001. (in Chinese).' Taiwan J Public Health ;22:453~64. Chien, C. R. and T. H. H. Chen (2008). 'Mean Sojourn Time and Effectiveness of Mortality Reduction for Lung Cancer Screening with Computed Tomography (accepted).' Int J Cancer. Chien, C. R. and C. H. Yang (2006). 'Thoracic radiotherapy for stage IV non-small cell lung cancer.' Radiother Oncol 78: 110; author reply 110-1. Chiou HL, W. M., Liaw YC, Cheng YW, Wong RH, Chen CY, Lee H. (2003). 'The presence of human papillomavirus type 16/18 DNA in blood circulation may act as a risk marker of lung cancer in Taiwan.' Cancer. 2003 Mar 15;97(6):1558-63. Chirikos, T. N., T. Hazelton, et al. (2002). 'Screening for lung cancer with CT: a preliminary cost-effectiveness analysis.' Chest 121: 1507-14. Chouaid, C., L. Molinier, et al. (2004). 'Economics of the clinical management of lung cancer in France: an analysis using a Markov model.' Br J Cancer 90: 397-402. Clark, M. M., L. S. Cox, et al. (2004). 'Effectiveness of smoking cessation self-help materials in a lung cancer screening population.' Lung Cancer 44: 13-21. Cochrane (2000). 'Chemotherapy for non-small cell lung cancer.' Cochrane Library, Issue 2. Oxford: Update Software, 2002. Colice, G. L., J. Rubins, et al. (2003). 'Follow-up and surveillance of the lung cancer patient following curative-intent therapy.' Chest 123: 272S-283S. Curran WJ (2003). 'Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III nsclc: RTOG 9410. .' Day, N. E. (1985). 'Estimating the sensitivity of a screening test.' J Epidemiol Community Health 39: 364-6. Delaney, G., M. Barton, et al. (2003). 'A model for decision making for the use of radiotherapy in lung cancer.' Lancet Oncol 4: 120-8. Devesa, S. S., G. L. Shaw, et al. (1991). 'Changing patterns of lung cancer incidence by histological type.' Cancer Epidemiol Biomarkers Prev. 1: 29-34. Diederich, S., M. Thomas, et al. (2004). 'Screening for early lung cancer with low-dose spiral computed tomography: results of annual follow-up examinations in asymptomatic smokers.' Eur Radiol 14: 691-702. Dillman RO, S. S., Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF 3rd, Green MR. (1990). 'A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.' N Engl J Med. 1990 Oct 4;323(14):940-5. Doll, R., R. Peto, et al. (1994). 'Mortality in relation to smoking: 40 years' observations on male British doctors.' Bmj 309: 901-11. Finkelstein M, K. R., Suranyi G. (1981). 'Mortality among workers receiving compensation for asbestosis in Ontario.' Can Med Assoc J. 1981 Aug 1;125(3):259-62. Flehinger BJ, K. M., Melamed MR. (1988). 'Natural history of adenocarcinoma-large cell carcinoma of the lung: conclusions from screening programs in New York and Baltimore.' J Natl Cancer Inst. 1988 May 4;80(5):337-44. Flehinger BJ, M. M., Zaman MB, Heelan RT, Perchick WB, Martini N. (1984). 'Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Memorial Sloan-Kettering study.' Am Rev Respir Dis 1984;130:555-60. Fletcher RH, F. S. (2005). Clinical epidemiology: the Essentials. . Force, U. S. P. S. T. (2004). 'Lung cancer screening: recommendation statement.' Ann Intern Med 140: 738-9. Ford, L. G., C. P. Hunter, et al. (1987). 'Effects of patient management guidelines on physician practice patterns: the Community Hospital Oncology Program experience.' J Clin Oncol 5: 504-11. Furuse K, F. M., Kawahara M (1999). 'Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.' J Clin Oncol. 1999 Sep;17(9):2692-9. Garg, K., R. L. Keith, et al. (2002). 'Randomized controlled trial with low-dose spiral CT for lung cancer screening: feasibility study and preliminary results.' Radiology 225: 506-10. Gatzemeier, U., A. Pluzanska, et al. (2007). 'Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.' J Clin Oncol 25: 1545-52. Geddes, D. M. (1979). 'The natural history of lung cancer: a review based on rates of tumour growth.' Br J Dis Chest. 1979;731-17. Ginsberg, R. J. and L. V. Rubinstein (1995). 'Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.' Ann Thorac Surg 60: 615-22; discussion 622-3. Gohagan, J. K., P. M. Marcus, et al. (2005). 'Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer.' Lung Cancer 47: 9-15. Goldstraw, P., J. Crowley, et al. (2007). 'The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.' J Thorac Oncol 2: 706-14. Goss G, P. L., Newman TE, Evans WK, Browman G. (1998). 'Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small-cell lung cancer. Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.' Cancer Prev Control. 1998 Feb;2(1):32-9. Gould, M. K., C. D. Berg, et al. (2007). 'CT Screening for Lung Cancer.' N Engl J Med 356: 743-747. Greene FL, P. D., Fleming ID, Fritz , Balh CM, Haller DG, and Morrow M (2002). 'AJCC cancer staging manual-6th ed. .' New York: Spriger-Verlag Group., P. M.-a. T. (1998). 'Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group.' Lancet. 1998 Jul 25;352(9124):257-63. Henschke, C. I., D. F. Yankelevitz, et al. (2006). 'Survival of patients with stage I lung cancer detected on CT screening.' N Engl J Med 355: 1763-71. Henschke, C. I., R. Yip, et al. (2006). 'Computed tomography screening for lung cancer: prospects of surviving competing causes of death.' Clin Lung Cancer 7: 323-5. Hogan, C., J. Lunney, et al. (2001). 'Medicare Beneficiaries' Costs Of Care In The Last Year Of Life.' Health Aff 20: 188-195. Hsieh, H. J., T. H. Chen, et al. (2002). 'Assessing chronic disease progression using non-homogeneous exponential regression Markov models: an illustration using a selective breast cancer screening in Taiwan.' Stat Med 21: 3369-82. HYDE L, Y. J., WILSON R, PATNO ME. (1965). 'CELL TYPE AND THE NATURAL HISTORY OF LUNG CANCER.' JAMA. 1965 Jul 5;193:52-4. JP Pignon, R. A., DC Ihde, DH Johnson, MC Perry, RL Souhami, O Brodin, RA Joss, MS Kies, B Lebeau, and et al. (1992). 'A meta-analysis of thoracic radiotherapy for small-cell lung cancer.' NEJM 1992;327:1618-1624. Kaneko, S., K. B. Ishikawa, et al. (2003). 'Projection of lung cancer mortality in Japan.' Cancer Sci 94: 919-23. Klasa RJ, M. N., Coldman AJ (1991). 'Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung.' J Clin Oncol. 1991 Mar;9(3):499-508. Knudsen, A. B., P. M. McMahon, et al. (2007). 'Use of modeling to evaluate the cost-effectiveness of cancer screening programs.' J Clin Oncol 25: 203-8. Ko YC, C. L., Lee CH, Huang JJ, Huang MS, Kao EL, Wang HZ, Lin HJ. (2000). 'Chinese food cooking and lung cancer in women nonsmokers.' Am J Epidemiol. 2000 Jan 15;151(2):140-7. Le Chevalier T, A. R., Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY, Laplanche A. (1991). 'Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.' J Natl Cancer Inst. 1991 Mar 20;83(6):417-23. Lee CH, K. Y., Goggins W, Huang JJ, Huang MS, Kao EL, Wang HZ. (2000). 'Lifetime environmental exposure to tobacco smoke and primary lung cancer of non-smoking Taiwanese women.' Int J Epidemiol. 2000 Apr;29(2):224-31. Lee, C. I. and H. P. Forman (2007). 'CT screening for lung cancer: implications on social responsibility.' AJR Am J Roentgenol 188: 297-8. Lee LT, L. W., Lin RS, Chen SC, Chen CY, Luh KT, Chen CJ. (1994). 'Age-period-cohort analysis of lung cancer mortality in Taiwan, 1966-1990.' Anticancer Res. 1994 Mar-Apr;14(2B):673-6. Levin ML, T. M., Frost JK, Ball WC Jr. (1982). 'Lung cancer mortality in males screened by chest X-ray and cytologic sputum examination: a preliminary report.' Recent Results Cancer Res. 1982;82:138-46. Liaw GM, C. C. (1997). 'Epidemiologic Characteristics, Risk Factors, and Control Strategies of Primary Lung Cancer.' Chinese Journal of Public Health1987;16(5): 民86.10 頁375-395. Liaw, K. M. and C. J. Chen (1998). 'Mortality attributable to cigarette smoking in Taiwan: a 12-year follow-up study.' Tob Control 7: 141-8. Liaw YP, H. Y., Lien GW. (2005). 'Patterns of lung cancer mortality in 23 countries: application of the age-period-cohort model.' BMC Public Health. 2005 Mar 5;5(1):22. Lin, P., Y. M. Hsueh, et al. (2003). 'Analysis of NQO1, GSTP1, and MnSOD genetic polymorphisms on lung cancer risk in Taiwan.' Lung Cancer. 2003 May;40(2):123-9. . Luh KT, C. D. (1992). '[Primary lung cancer in Taiwan][Article in Chinese].' J Formos Med Assoc. 1992 Mar;91 Suppl 1:S1-7. . MacRedmond R, e. a. (2004). 'Screening for lung cancer using low dose CT scanning.' Thorax 59: 237-241. Mahadevia, P. J., L. A. Fleisher, et al. (2003). 'Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis.' Jama 289: 313-22. Maher, M. M., M. K. Kalra, et al. (2004). 'Application of rational practice and technical advances for optimizing radiation dose for chest CT.' J Thorac Imaging 19: 16-23. Manser, R., A. Dalton, et al. (2005). 'Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.' Lung Cancer 48: 171-85. Manser RL, L. B. Irving, et al. (2003). 'Screening for lung cancer: a systematic review and meta-analysis of controlled trials.' Thorax 58: 784-9. Marcus PM, E. J. Bergstralh, et al. (2006). 'Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis.' J Natl Cancer Inst 98: 748-56. Marino P, P. S., Preatoni A, Cantoni A, Invernizzi F. (1994). 'Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature.' Chest. 1994 Sep;106(3):861-5. Marshall, D., K. N. Simpson, et al. (2001). 'Potential cost-effectiveness of one-time screening for lung cancer (LC) in a high risk cohort.' Lung Cancer 32: 227-36. Marshall, D., K. N. Simpson, et al. (2001). 'Economic decision analysis model of screening for lung cancer.' Eur J Cancer 37: 1759-67. Marugame, T., T. Sobue, et al. (2005). 'Lung cancer death rates by smoking status: comparison of the Three-Prefecture Cohort study in Japan to the Cancer Prevention Study II in the USA.' Cancer Sci 96: 120-6. McGovern, P. M., C. R. Gross, et al. (2004). 'False-positive cancer screens and health-related quality of life.' Cancer Nurs 27: 347-52. McMahon, P. M. and D. C. Christiani (2007). 'Computed tomography screening for lung cancer.' Bmj 334: 271. McWilliams, A. M., J. R. Mayo, et al. (2006). 'Lung cancer screening using multi-slice thin-section computed tomography and autofluorescence bronchoscopy.' J Thorac Oncol 1: 61-8. Melamed, M., B. J. Flehinger, et al. (1984). 'Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York.' Chest 86: 44-53. Meropol, N. J. and K. A. Schulman (2007). 'Cost of cancer care: issues and implications.' J Clin Oncol 25: 180-6. Miller A (2004). 'Lung cancer screening using low-dose high-resolution CT scanning in a high-risk workforce: 3500 nuclear fuel workers in three US states.' Ministry_Of_Interior (2007). 'accessed on 2007/5/26 at http://www.moi.gov.tw/stat/english.asp.' Molinier, L., C. Combescure, et al. (2006). 'Cost of lung cancer: a methodological review.' Pharmacoeconomics 24: 651-9. Morrison, A. S. (1998). ' Screening. In Rothman K.J., Greenland S (eds). Modern Epidemiology 2nd edition. Philadelphia, LIppincott Williams & Wilkins. .' Mountain, C. F. (1997). 'Revisions in the International System for Staging Lung Cancer.' Chest 111: 1710-7. Mulshine, J. L. and D. C. Sullivan (2005). 'Lung Cancer Screening.' N Engl J Med 352: 2714-2720. Murray N, L. R., Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D (1999). 'Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.' J Clin Oncol. 1999 Aug;17(8):2300-8. Myles, J. P., R. M. Nixon, et al. (2003). 'Bayesian evaluation of breast cancer screening using data from two studies.' Stat Med 22: 1661-74. National_Cancer_Database (2008). 'accessed on 2008/1/4, at http://web.facs.org/ ncdbbmr/survival8.cfm.' National_Lung_Screening_Trial (2008). ' Accessed 2008/1/2, at http://www.cancer.gov/nlst.' NCCN_NSCLC (2004). ' http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf [last accessed 2004/9/1].' NCCN_NSCLC (2007). NCCN Clinical Practice Guidelines in Oncology [homepage on the internet]. Non-small cell lung cancer v.1.2007 (Accessed May 2007 at http://www.nccn.org/ professionals/physician_gls/PDF/nscl.pdf). NCCN_SCLC (2004). ' http://www.nccn.org/professionals/physician_gls/PDF/sclc.pdf [last accessed 20047/9/1].' NCI_NSCLC (2004). 'Http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/ healthprofessional [last accessed: 2004/9/1].' NCI_NSCLC (2007). 'accessed 2007/4/1 at http://www.cancer.gov/cancertopics/pdq/treatment /non-small-cell-lung/healthprofessiona.' NCI_SCLC (2004). ' Http://www.cancer.gov/cancertopics/pdq/treatment/small-cell-lung/ healthprofessional [last accessed: 2004/9/1].' NCI_SCLC (2007). 'accessed on 2007/4/1 at http://www.cancer.gov/cancertopics/pdq/treatment/ small-cell-lung/healthprofessional.' Noda K, N. Y., Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group (2002). 'Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.' N Engl J Med. 2002 Jan 10;346(2):85-91. Novello, S., C. Fava, et al. (2005). 'Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers.' Ann Oncol 16: 1662-6. NSCLC_Collaborative_Group. (2000). 'Chemotherapy for non-small cell lung cancer. Non-small Cell Lung Cancer Collaborative Group.' Cochrane Database Syst Rev: CD002139. Okamoto, N. (2000). 'Cost-effectiveness of lung cancer screening in Japan.' Cancer 89: 2489-93. Ostroff, J. S., N. Buckshee, et al. (2001). 'Smoking cessation following CT screening for early detection of lung cancer.' Prev Med 33: 613-21. Ozols, R. F., R. S. Herbst, et al. (2007). 'Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.' J Clin Oncol 25: 146-62. Pastorino, U., M. Bellomi, et al. (2003). 'Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results.' Lancet 362: 593-7. Patz, E. F., Jr., S. J. Swensen, et al. (2004). 'Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations.' J Clin Oncol 22: 2202-6. Perng, R. P., C. Y. Chen, et al. (2007). 'Revisit of 1997 TNM Staging System--Survival Analysis of 1112 Lung Cancer Patients in Taiwan.' Jpn J Clin Oncol 37: 9-15. Picozzi G, P. E., Lopez Pegna A, Bartolucci M, Roselli G, De Francisci A, Gabrielli S, Masi A, Villari N, Mascalchi M. (2005). 'Screening of lung cancer with low dose spiral CT: results of a three year pilot study and design of the randomised controlled trial 'Italung-CT'.' Radiol Med (Torino) 109: 17-26. Potosky, A. L., S. Saxman, et al. (2004). 'Population variations in the initial treatment of non-small-cell lung cancer.' J Clin Oncol 22: 3261-8. Prevost, T. C., G. Launoy, et al. (1998). 'Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches.' Am J Epidemiol 148: 609-19. Saccomanno G, A. V., Auerbach O, Saunders RP, Brennan LM. (1974). 'Development of carcinoma of the lung as reflected in exfoliated cells.' Cancer. 1974 Jan;33(1):256-70. Sandler, A., R. Gray, et al. (2006). 'Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.' N Engl J Med 355: 2542-50. Saunders, M., S. Dische, et al. (1997). 'Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee.' Lancet 350: 161-5. Schiller, J. H., D. Harrington, et al. (2002). 'Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.' N Engl J Med 346: 92-8. Shaham, D., R. Breuer, et al. (2006). 'Computed tomography screening for lung cancer: applicability of an international protocol in a single-institution environment.' Clin Lung Cancer 7: 262-7. Silvestri, G. A. (2007). 'Screening for lung cancer in a high-risk group: but I still haven't found what I'm looking for.' Eur Respir J 29: 6-7. Sobue, T., N. Moriyama, et al. (2002). 'Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project.' J Clin Oncol 20: 911-20. Sone, S., F. Li, et al. (2001). 'Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner.' Br J Cancer 84: 25-32. Souquet PJ, C. F., Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, et al. (1993). 'Polychemotherapy in advanced non small cell lung cancer: a meta-analysis.' Lancet. 1993 Jul 3;342(8862):19-21. Spira A, E. D. (2004). 'Multidisciplinary management of lung cancer.' N Engl J Med 350: 379-92. Stephenson, S. M., K. F. Mech, et al. (2005). 'Lung cancer screening with low-dose spiral computed tomography.' Am Surg 71: 1015-7. Swensen, S. J., J. R. Jett, et al. (2003). 'Lung cancer screening with CT: Mayo Clinic experience.' Radiology 226: 756-61. Taiwan_Caner_Registry (2007). 'http://crs.cph.ntu.edu.tw/crs_c/annual.html [last accessed: 2007/4/1].' Thatcher, N., A. Chang, et al. (2005). 'Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).' The Lancet 366: 1527-1537. Tiitola, M., L. Kivisaari, et al. (2002). 'Computed tomography screening for lung cancer in asbestos-exposed workers.' Lung Cancer 35: 17-22. Turrisi AT 3rd, K. K., Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. (1999). 'Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.' N Engl J Med. 1999 Jan 28;340(4):265-71. Twombly, R. (2007). 'Lung cancer screening debate continues despite international CT study results.' J Natl Cancer Inst 99: 190-5. van de Mheen, P. J. and L. J. Gunning-Schepers (1996). 'Differences between studies in reported relative risks associated with smoking: an overview.' Public Health Rep 111: 420-6; discussion 427. van Iersel, C. A., H. J. de Koning, et al. (2007). 'Risk-based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON).' Int J Cancer 120: 868-74. Walter, S. D. and N. E. Day (1983). 'Estimation of the duration of a pre-clinical disease state using screening data.' Am J Epidemiol 118: 865-86. Walter SD, K. A., Parkin DM, Reissigova J, Adamec M, Khlat M. (1992). 'The natural history of lung cancer estimated from the results of a randomized trial of screening.' Cancer Causes Control. 1992 Mar;3(2):115-23. Wang, T. N., S. J. Chang, et al. (1994). '[Standardized incidence ratios for cancers in Taiwan aborigines, 1981-1987][Article in Chinese].' Gaoxiong Yi Xue Ke Xue Za Zhi. 1994 Jul;10(7):392-404. Warde P, P. D. (1992). 'Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis.' J Clin Oncol. 1992 Jun;10(6):890-5. Wardwell, N. R. and P. P. Massion (2005). 'Novel strategies for the early detection and prevention of lung cancer.' Semin Oncol 32: 259-68. Website. http://www.mrc-bsu.cam.ac.uk/bugs/welcome.shtml [last accessed: 2006/7/22]. Weick J.K, Crowley J., Natale R.B., et al. (1991). 'A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study.' J Clin Oncol 9: 1157-1162. Weissflog, D., H. Matthys, et al. (2001). '[Epidemiology and costs of lung cancer in Germany].' Pneumologie 55: 333-8. Wen, C. P., S. P. Tsai, et al. (2004). 'The mortality risks of smokers in Taiwan: Part I: cause-specific mortality.' Prev Med 39: 528-35. Wen, C. P., S. P. Tsai, et al. (2005). 'Smoking attributable mortality for Taiwan and its projection to 2020 under different smoking scenarios.' Tob Control 14 Suppl 1: i76-80. Williams, C. (2003). 'Evidence-based oncology. London: BMJ Books 2003.' Wisnivesky, J. P., M. Bonomi, et al. (2005). 'Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer.' Chest 128: 1461-7. Wisnivesky, J. P., A. I. Mushlin, et al. (2003). 'The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening.' Chest 124: 614-21. Wu PF, C. T., Wang TN, Huang MS, Ho PS, Lee CH, Ko AM, Ko YC. (2005). 'Birth cohort effect on lung cancer incidence in Taiwanese women 1981-1998.' European Journal of Cancer 41: 1170-1177. Yang CY, C. M., Chiu JF, Tsai SS. (1999). 'Female lung cancer and petrochemical air pollution in Taiwan.' Arch Environ Health. 1999 May-Jun;54(3):180-5. . Yang SP, L. K., Kuo SH, Lin CC. (1984). 'Chronological observation of epidemiological characteristics of lung cancer in Taiwan with etiological consideration--a 30-year consecutive study.' Jpn J Clin Oncol. 1984 Mar;14(1):7-19. Young JL Jr, R. S., Ries LAG, , Fritz AG, Hurlbut AA, editors. (2001). 'SEER Summary Staging Manual-2000: Codes and Coding Instructions [monograph on the Internet]. Bethesda, MD: National Cancer Institute, NIH Pub. No01-4969; 2001 [cited 2006 Nov 1]. Available from: http://seer.cancer.gov/tools/ssm.' | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27068 | - |
dc.description.abstract | 背景及目的:肺癌是全球主要癌症死因。目前並無肺癌篩檢之有效策略。以胸部電腦斷層作為肺癌篩檢有許多爭論,目前有兩個大型隨機分派臨床試驗進行中(NELSON 及 NLST),但短期內不會有結果。故本研究目的在於(1)研究不同年齡及世代下之肺癌發生率(2)相應於不同篩檢工具下之肺癌平均滯留時間(3)配合上述(1)(2),發展依決策分析模式以作為肺癌篩檢之經濟評估。
方法:我們以決策分析軟體TreeAgePro建構一個五階段馬可夫模式以便模擬肺癌篩檢。主要評估點為有效性與成本效用,其中有效性以預期人年差異來表示,而成本效用以增加成本效用比來表示,其中效用以品質校正人年(QALY)來表示。另外,我們建立五階段馬可夫模式中所需之重要參數(發生率、平均滯留時間、及治療順從性),而其他所需之參數則以西方文獻為主。我們以貝氏年齡期間世代模式分析癌症登記資料來估計發生率。對相應於電腦斷層的平均滯留時間,我們用貝氏三階段馬可夫模式分析文獻報告來估計。至於相應於胸部愛克斯光的平均滯留時間,我們則用貝氏三階段馬可夫模式分析一伺機性篩檢族群來估計。我們另以回歸及描述性統計來分析醫院癌症登記資料以便估計治療順從性。在完成模式建構與參數估計後,我們比較了模式估計值與文獻報告來做模式驗證。比較的項目包含不同期別之個案發現率,不同期別之個案存活率,及不同期別之治療費用。最後我們以上述之模式與參數進行不同肺癌篩檢情境下之模擬。主要的模擬情境是參考NELSON試驗(61歲高危險性吸煙者進行三次電腦斷層篩檢或只是觀察),但我們也模擬了其他情境。 結果:我們發現台灣肺癌發生率就男性而言在公元2000年後已稍微下降,但就女性而言仍在稍微上升。在1996年,61歲台灣男性之肺癌發生率(1/100000人年)為102 (95%信賴區間:80∼127),而女性則為31(22∼44)。到了2002年,相對應的值是123(99~147)及58(45∼75)。我們估計肺癌相應於電腦斷層的平均滯留時間是2.06年(95%信賴區間:0.42∼3.83),而相應於胸部愛克斯光的平均滯留時間是5.51個月(95%信賴區間:4.04∼7.12)。我們估計晚期肺癌的治療順從性為40%。在模式驗證方面,我們發現模式估計值與文獻報告尚稱接近。在不同期別之個案發現率上,我們預估篩檢可在受檢者中發現1.1%早期肺癌及1.4%肺癌,此與文獻相近(1.3% & 1.5%)。在不同期別之個案存活率上,我們預估早期與晚期肺癌之五年存活率分別為62%∼77% & 0∼1%,此亦與文獻相近(54∼73% & 1∼7%)。至於不同期別之治療費用(美金,USD),我們預估早期與晚期肺癌分別為25183 & 22372,此亦與文獻相近(25050 & 20691)。最後,在我們的主要模擬情境(NELSON)上,我們預估預期人年差異為0.018 年(95%信賴區間-0.04∼0.07),而增加成本效用比(USD/QALY)為125171 (社會觀點)(如以付費者觀點則為 237145)。若考慮不同情境,如密集篩檢,每年電腦斷層篩檢相較於每三年一次可減少肺癌死亡率(2.1% vs 2.4%)但不合成本效用。相較於愛克斯光篩檢,電腦斷層篩檢的增加成本效用比(USD/QALY)為89349。如果在發生率較低的國家進行篩檢(比如以台灣之吸菸者就2002年的發生率0.00171~0.00185而言),預期人年差異為0.0067~0.0071 年,而增加成本效用比(USD/QALY)為447258~752571。 結論:(1)台灣肺癌發生率就男性而言在公元2000年後已稍微下降,但就女性而言仍在稍微上升(2)相應於胸部愛克斯光較短的平均滯留時間,以胸部電腦斷層做肺癌篩檢相對有效(3)利用(1)及(2)的成果所進行的醫療經濟評估顯示以胸部電腦斷層做肺癌篩檢可增加預期人年差異及減少肺癌死亡率,但相較於其他癌症篩檢其增加成本效用比仍稍許偏高。 | zh_TW |
dc.description.abstract | Background & Objectives: Lung cancer is the leading cause of cancer death world wide. There is no effective screening modality so far, and screening computed tomography (CT) is highly debated. There were two large ongoing randomized trials comparing CT v.s. observation (the Dutch-Belgian randomised lung cancer screening trial (NELSON)) or chest xray (CXR)(national lung screening trial, NLST), with results awaiting. The aims of this study were to (1) estimate the baseline incidence of lung cancer by age, period, cohort, (2) to estimate the mean sojourn time ( MST) of lung cancer by different screening modality; (3) to develop a decision modeling for economic evaluation of lung cancer screening by different intervals and screening modalities based on (1) and (2).
Methods: We build up a five state Markov model to simulate the effectiveness (mainly presented as incremental life expectancy, ILE) and cost-utility analysis (presented as incremental cost-utility (in terms of quality-adjusted life year, QALY) ratio, ICUR) of lung cancer screening. Important parameters (incidence, mean sojourn time (MST), and treatment compliance) were established separately in order to implement the model. As to incidence, lung cancer cases (n=44139) diagnosed between 1996 and 2002 in Taiwan were analyzed by using a Bayesian age-period-cohort (BAPC) model. Age-adjusted standardized incidence rate (ASIR, per 100000 person-year) were calculated. As to MST by CT, data from six prospective CT screening studies were retrieved based on systematic literature review. The MST in association with the natural history of lung cancer depicted by a three-state Markov model was estimated with a Bayesian approach. As to MST by CXR, we collected data on demographic features, histology type, survival status, history of smoking, and asymptomatic or symptomatic status in light of chief complaint at diagnosis retrieved from medical records based on institutional cancer registry for lung cancer patients with prior non-diagnostic CXR (n=221) as an opportunistic screening cohort. The MST for the natural history of lung cancer underpinning a three-state Markov model was estimated with a Bayesian approach. As to treatment compliance, it was estimated from hospital cancer registry (from year 1991 to 2002, n=4565) via descriptive analysis. Other complimentary parameters were cited based on western literatures. Model validation was based on comparison between estimates and reported literatures for stage specific case identification, stage specific survival, and stage specific treatment related cost. Finally, effectiveness and cost-utility analysis of lung cancer screening were estimated via the above mentioned model and parameters for our primary and complementary scenarios. The primary scenario was a NELSON like (for selected smoker with median age 61 y/o) setting. Results: The prediction of our BAPC model was close to observation, and showed slightly decreasing incidence after around year 2000 for male but still slightly increasing for female. The median (95%CI) estimated annual incidence rate (/100000) of lung cancer in 61 year-old Taiwanese would be 102 (80~127) for male and 31 (22~44) for female in year 1996. The corresponding figures in year 2002 would be 123 (99~147) and 58 (45~75) respectively. The median (95% confidence interval, 95%CI) MST of lung cancer with screening CT was estimated as 2.06 (0.42~3.83) years. The median (95%CI) MST by screening CXR was estimated as 5.51 (4.04~7.12) months. Small cell lung carcinoma was even statistically significantly shorter MST than non-small cell lung carcinoma (3.01 months (3-3.98) versus 6.07 (4.44-8.25) months). The treatment compliance rates were 40% for advanced stage diseases. Model validation revealed comparable results in case finding (estimated/reported cases: 1.1%/1.3% for early stage disease and 1.4%/1.5% for all lung cancer), stage-specific survival (estimated/reported 5-year survival: (0.62~0.77)/(0.54~0.73) for early stage disease and (0~0.01)/(0.01~0.07) for advanced disease), and treatment related cost (US dollars, USD)(estimated/reported: 25183/25050 for early stage and 22372/20691 for advanced stage disease). In NELSON like setting, the median (95%CI) ILE would be 0.018 (-0.04~0.07) year. The mean ICUR (USD/QALY) would be 125171 in societal point of view (237145 if in payer’s point of view). In consider of the impact of different screening schedules, annual CT screening is associated with less lung cancer death when compared with three-yearly screening (percentage of lung cancer death: 2.1% vs 2.4%), but it is not cost-benefit when utility and cost was taken into account. In consider of different screening modality, CT screening vs CXR screening is more cost-benefit when compared with our main scenario (mean ICUR: 89348). If screening program was performed in a country with low incidence rate such as Taiwan (incidence of lung cancer for smoker in the NELSON like setting being 0.00171~ 0.00185 in year 2002), the median ILE would be 0.0067~0.0071 year. The mean ICUR (USD/QALY) would be 447258~752571. Conclusion: (1) Lung cancer incidence in Taiwan was slightly decreasing for male but slightly increasing for female. (2) The shorter mean sojourn time by using CXR as compared with MST by CT strongly suggests that CT screening may be more effective in early detection of lung cancer in screening. (3) Health economic evaluation based on (1) & (2) revealed that lung cancer screening with CT may lead to an increase in life expectancy and reduce lung cancer mortality, but the incremental cost-utility ratio remained high when compared with other cancer screening. | en |
dc.description.provenance | Made available in DSpace on 2021-06-12T17:54:49Z (GMT). No. of bitstreams: 1 ntu-97-D91842007-1.pdf: 4599639 bytes, checksum: 8088baa1be68556e75d44864789f4f3b (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 謝辭………………………………………………………………………ii
中文摘要……………………………………………………………iii-v Abstract……………………………………………………………vi-ix Index……………………………………………………………x-xii I. Introduction……………………………………………………1-2 II. Literature Reviews …………………………………………3-32 II-1: Evidence base of lung cancer screening modality …………………......................... 7-9 II-2: Criteria for deciding whether screening should be included in preventive care ……………………………………………………………........................................ 10-11 II-2a: Disease burden of lung cancer for general and high risk population …………………………………………………………………...................... 12-20 II-2b: Screening modality related factors …………………………………...................... 21-27 II-2c: Treatment-related factors …………………………………………......................... 28-30 II-3: Modeling of effectiveness or cost-effectiveness for cancer screening ………………………………………………………………………………… 31-32 III. Objective & Study Design ………………………………………………………….. 33-44 III-A: Model construction …………………………………………………..................... 34 III-B: Establishment of important parameters (incidence, MST, compliance) ……………………………………………………………………………... 35-39 III-C: Model validation ……………………………………………………..................... 40-43 III-D: Evaluation of lung cancer screening by model simulation ………………………. 44 IV. Methods ……………………………………………………………........................... 45-89 IV-A: Model construction …………………………………………………..................... 45-57 IV-B: Establishments of important endemic parameters (incidence, MST, & compliance) …………………………………………………………………………… 58-87 IV-B-1: Incidence …………………………………………………………...................... 58-64 IV-B-2a: MST-CT ……………………………………………………………………….. 65-74 IV-B-2b: MST-CXR ………………………………………………………...................... 75-82 IV-B-3: Treatment compliance ……………………………………………...................... 83-87 IV-C: Model validation ……………………………………………………..................... 88 IV-D: Evaluation of lung cancer screening by model simulation……………………….. 88-89 V. Results ………………………………………………………………………………... 90-109 V-A: Model construction ……………………………………………………………….. 90 V-B: Establishments of important endemic parameters (incidence, MST, & compliance) …………………………………………………………………………....... 90-99 V-B-1: Incidence ………………………………………………………………………… 90-91 V-B-2a: MST-CT …………………………………………………………....................... 92-93 V-B-2b: MST-CXR ……………………………………………………………………… 94-97 V-B-3: Treatment compliance …………………………………………………………... 98-99 V-C: Model validation ……………………………………………………….................. 100-103 V-D: Evaluation of lung cancer screening by model simulation …………....................... 104-109 VI. Discussion & Prospective …………………………………………………………... 110-114 VII. Conclusions ……………………………………………………………………….. 115 VIII. References ………………………………………………………............................ 116-126 VIII. Appendix: 127-130 Appendix A: Mean Sojourn Time and Effectiveness of Mortality Reduction for Lung Cancer Screening with Computed Tomography (Int J Cancer 2008 in press) ………………………………………………………………………………. 127-128 Appendix B: Estimation of Mean Sojourn Time for Lung Cancer by Chest X-ray screening with a Bayesian Approach (Lung Cancer 2008: in revision) ………….. 129 Appendix C: Trends in the pattern of care for lung cancer and their correlation with new clinical evidence: experiences in a university-affiliated medical center (Amer J Med Qual 2006) ………………………………………………………….. 130 | |
dc.language.iso | en | |
dc.title | 肺癌篩檢之評估 | zh_TW |
dc.title | Evaluation of lung Cancer Screening | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 張淑惠,楊泮池,嚴明芳,洪志宏,陳志毅 | |
dc.subject.keyword | 肺癌,篩檢,電腦斷層,發生率,平均滯留時間,照護模式,有效性,成本效用分析, | zh_TW |
dc.subject.keyword | lung cancer,screening,computed tomography,incidence,mean sojourn time,pattern of care,effectiveness,cost-utility analysis, | en |
dc.relation.page | 130 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-02-04 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 預防醫學研究所 | zh_TW |
Appears in Collections: | 流行病學與預防醫學研究所 |
Files in This Item:
File | Size | Format | |
---|---|---|---|
ntu-97-1.pdf Restricted Access | 4.49 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.